Private company

Gritstone bio, Inc.

In its 2024 annual report the company says: “We are a clinical-stage biotechnology company focused on combining immunological insights with proprietary technologies and capabilities to develop next-generation vaccines.”3 It is headquartered in Emeryville, California.1

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersEmeryville, California1
  • Incorporated inDE2
  • Business address5959 Horton Street, Suite 300, Emeryville, Ca 946082
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company focused on combining immunological insights with proprietary technologies and capabilities to develop next-generation vaccines. Specifically, we discover, develop, manufacture and deliver vaccine-based immunotherapy candidates against cancer and infectious disease. Our goal is to unlock more potent and durable immunity by harnessing vaccine innovation. We aim to achieve that goal by leveraging our in-house capabilities and technologies to address the shortcomings of currently available vaccines and immunotherapies.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-854.3%Operating margin4
-847.3%Net margin4
-18.1%Revenue growth, 20234
-267.1%Return on equity4
0.77×Debt to equity4
-$126.2MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development97¢$127.2M
  • Interest3¢$4.0M

Out of $16.3M in revenue.4 The company lost money this year.

Financial statements

Revenue5674$16.3M in 2023+1277% since 2018
0$20.0M$40.0M$60.0M2018: $1.2M$1.2M20182019: $4.4M$4.4M2019+268%2020: $4.0M$4.0M2020−8%2021: $48.2M$48.2M2021+1094%2022: $19.9M$19.9M2022−59%2023: $16.3M$16.3M2023−18%
Operating income85674-$139.6M in 2023+234% since 2017
-$150.0M-$100.0M-$50.0M02017: -$41.8M-$41.8M20172018: -$65.6M-$65.6M2018+57%2019: -$97.9M-$97.9M2019+49%2020: -$106.0M-$106.0M2020+8%2021: -$75.2M-$75.2M2021−29%2022: -$120.4M-$120.4M2022+60%2023: -$139.6M-$139.6M2023+16%
Net income85674-$138.5M in 2023+235% since 2017
-$150.0M-$100.0M-$50.0M02017: -$41.4M-$41.4M20172018: -$64.8M-$64.8M2018+57%2019: -$94.4M-$94.4M2019+46%2020: -$105.3M-$105.3M2020+12%2021: -$75.1M-$75.1M2021−29%2022: -$119.7M-$119.7M2022+59%2023: -$138.5M-$138.5M2023+16%
Fiscal year2017201820192020202120222023
Revenue$1.2M5$4.4M6$4.0M7$48.2M4$19.9M4$16.3M4
Research and development$35.7M8$55.0M5$82.9M6$88.6M7$97.5M4$111.4M4$127.2M4
Operating expenses$123.4M4$140.4M4$156.0M4
Operating income-$41.8M8-$65.6M5-$97.9M6-$106.0M7-$75.2M4-$120.4M4-$139.6M4
Interest$12.0K7$37.0K4$1.2M4$4.0M4
Net income-$41.4M8-$64.8M5-$94.4M6-$105.3M7-$75.1M4-$119.7M4-$138.5M4
Earnings per share-$2.797-$0.954-$1.324-$1.204
Earnings per share (diluted)-$2.797-$0.954-$1.324-$1.204
Shares (weighted, basic)78.9M shares490.9M shares4115.5M shares4
Shares (weighted, diluted)78.9M shares490.9M shares4115.5M shares4

Compare Gritstone bio, Inc. with another company

Corporate structure

Gritstone bio, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Gritstone bio, Inc.

  • Redmile Group, LLC Filed SCHEDULE 13G/A on Gritstone bio, Inc., latest Feb 14, 2025 (4 filings since Feb 14, 2022)
  • Morgan Stanley Filed SC 13G/A on Gritstone bio, Inc., latest Nov 7, 2024 (3 filings since Feb 8, 2024)
  • RedCo II Master Fund, L.P. Filed SC 13G on Gritstone bio, Inc., latest Oct 7, 2024
  • Point72 Asset Management, L.P. Filed SC 13G/A on Gritstone bio, Inc., latest Feb 14, 2024 (3 filings since Nov 1, 2022)
  • Frazier Life Sciences Public Fund, L.P. Filed SC 13G/A on Gritstone bio, Inc., latest Feb 13, 2024 (2 filings since Feb 14, 2023)
  • Avidity Partners Management LP Filed SC 13G/A on Gritstone bio, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • EcoR1 Capital, LLC Filed SC 13G/A on Gritstone bio, Inc., latest Feb 10, 2023 (2 filings since Feb 14, 2022)
  • Versant Venture Capital V, L.P. Filed SC 13G/A on Gritstone bio, Inc., latest Feb 9, 2023 (2 filings since Feb 11, 2022)
  • State Street Corporation Filed SC 13G/A on Gritstone bio, Inc., latest Feb 3, 2023 (2 filings since Feb 11, 2022)
  • BIOTECHNOLOGY VALUE FUND L P Filed SC 13G/A on Gritstone bio, Inc., latest Feb 14, 2022
  • FMR LLC Filed SC 13G/A on Gritstone bio, Inc., latest Feb 9, 2022
  • Wellington Management Portfolios (Dublin) Public Ltd Co Filed SC 13G/A on Gritstone bio, Inc., latest Feb 4, 2022
  • Gritstone bio, Inc. Emeryville, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Gritstone bio, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$49.7M4 Dec 31, 2023$48.8M4 Dec 31, 2022+1.9%
Accumulated depreciation$32.4M4 Dec 31, 2023$28.8M4 Dec 31, 2022+12.6%
Property and equipment, net$17.3M4 Dec 31, 2023$21.3M4 Dec 31, 2022−19.0%
Operating-lease assets (leased space)$66.8M4 Dec 31, 2023$17.5M4 Dec 31, 2022+282.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$63.0M4 Dec 31, 2023$55.5M4 Dec 31, 2022+13.5%
Marketable securities, current$16.3M4 Dec 31, 2023$116.4M4 Dec 31, 2022−86.0%
Marketable securities, non-current$04 Dec 31, 2023$4.0M4 Dec 31, 2022−100.0%
Debt securities available for sale$62.3M4 Dec 31, 2023$158.6M4 Dec 31, 2022−60.7%

Leadership

Who has led Gritstone bio, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Andrew R. Allen2018–2024

President

  1. Andrew R. Allen2018–2024

Chief financial officer

  1. Jean-Marc Bellemin2018
  2. Vassiliki Economides2021–2025

Chief operating officer

  1. Erin Jones2021–2024
20202025
Board members and other officers (23)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerKarin E. Joos named Oct 22, 2021 to Nov 8, 202238
  • President and Chief Executive OfficerAndrew Allen, M.D., Ph.D. named Oct 22, 202139
  • Chief Financial OfficerCelia Economides named Oct 22, 202139
  • DirectorElaine Jones, Ph.D. named Oct 22, 202139
  • DirectorRichard Heyman, Ph.D. named Oct 22, 202139

Former names

  • Gritstone Oncology, Inc.May 4, 2018 to Apr 23, 20212

Timeline

  1. Apr 4, 20258-K Bankruptcy or receivership; Unregistered sale of shares; Change to shareholders' rights40
  2. Feb 25, 20258-K Regulation FD disclosure41
  3. Feb 14, 20258-K Regulation FD disclosure42
  4. Jan 3, 20258-K Entered a material agreement; Bankruptcy or receivership; Completed an acquisition or sale43
  5. Dec 13, 20248-K Regulation FD disclosure44
  6. Nov 29, 20248-K Regulation FD disclosure45
  7. Nov 15, 20248-K Entered a material agreement; Bankruptcy or receivership; New debt or obligation46
  8. Oct 16, 20248-K Exit or restructuring costs; Listing notice or transfer47
  9. Oct 10, 20248-K Bankruptcy or receivership; Debt or obligation accelerated; Regulation FD disclosure48
  10. Oct 1, 20248-K Other events49
  11. Aug 13, 20248-K Results of operations50
  12. Jun 25, 20248-K Listing notice or transfer51
  13. Sep 27, 2018New chief executive Andrew R. Allen becomes CEO12

Calendar

When it reported results

  1. Aug 13, 2024Reported quarterly or annual results50
  2. May 9, 2024Reported quarterly or annual results52
  3. Mar 5, 2024Reported quarterly or annual results53
  4. Feb 12, 2024Reported quarterly or annual results54
  5. Nov 8, 2023Reported quarterly or annual results55
  6. Aug 9, 2023Reported quarterly or annual results56
  7. May 11, 2023Reported quarterly or annual results57
  8. Mar 9, 2023Reported quarterly or annual results58

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

223 filings to the SEC since October 2021: 4 annual reports, 9 quarterly reports, 40 major events, 88 insider forms, 24 large holders, 2 private raises, 56 other. The latest 20:

  1. Apr 8, 20254 EDGAR
  2. Apr 8, 20254 EDGAR
  3. Apr 8, 20254 EDGAR
  4. Apr 8, 20254 EDGAR
  5. Apr 8, 20254 EDGAR
  6. Apr 8, 20254 EDGAR
  7. Apr 8, 20254 EDGAR
  8. Apr 8, 20254 EDGAR
  9. Apr 4, 202515-12G EDGAR
  10. Apr 4, 20258-K EDGAR
  11. Mar 31, 2025EFFECT EDGAR
  12. Mar 31, 2025EFFECT EDGAR
  13. Mar 31, 2025EFFECT EDGAR
  14. Mar 31, 2025EFFECT EDGAR
  15. Mar 28, 2025S-8 POS EDGAR
  16. Mar 28, 2025S-8 POS EDGAR
  17. Mar 28, 2025S-8 POS EDGAR
  18. Mar 28, 2025S-8 POS EDGAR
  19. Mar 28, 2025S-8 POS EDGAR
  20. Mar 28, 2025S-8 POS EDGAR

The 223 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

14 open-market trades by officers, directors and large owners since October 2021: 1 buys and 13 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 18, 2024Economides VassilikiEVP, CHIEF FINANCIAL OFFICERSale12,000$0.02$240Form 4
May 16, 2024Allen Andrew RPRESIDENT AND CEOSale24,263$0.75$18.2KForm 4
May 16, 2024Jones ErinEVP, CHIEF OPERATING OFFICERSale13,749$0.75$10.3KForm 4
May 16, 2024Jooss KarinSEE REMARKSSale13,749$0.75$10.3KForm 4
May 16, 2024Hawryluk MatthewEVP, CHIEF BUSINESS OFFICERSale9,259$0.75$6.9KForm 4
May 16, 2024Economides VassilikiEVP, CHIEF FINANCIAL OFFICERSale13,749$0.75$10.3KForm 4
May 23, 2023Economides VassilikiEVP, CHIEF FINANCIAL OFFICERBuy12,000$1.90$22.8KForm 4
Dec 1, 2021Jones ErinEVP, CHIEF OPERATING OFFICERSale1,000$13.01$13.0KForm 4
Nov 1, 2021Jones ErinEVP, CHIEF OPERATING OFFICERSale1,000$11.14$11.1KForm 4
Nov 1, 2021Jones ErinEVP, CHIEF OPERATING OFFICERSale1,000$11.14$11.1KForm 4
Oct 4, 2021Jones ErinEVP, CHIEF OPERATING OFFICERSale1,000$10.71$10.7KForm 4
Oct 4, 2021Jones ErinEVP, CHIEF OPERATING OFFICERSale1,000$10.71$10.7KForm 4
Oct 1, 2021Jones ErinEVP, CHIEF OPERATING OFFICERSale1,000$10.68$10.7KForm 4
Oct 1, 2021Jones ErinEVP, CHIEF OPERATING OFFICERSale1,000$10.68$10.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Oct 24, 2022Raised $45 million in a private offering of equity Form D: $45 million offered in all Form D
  2. Sep 16, 2021Raised $55 million in a private offering of equity Form D: 10 investors so far Form D

SEC filer profile

How Gritstone bio, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGritstone bio, Inc.1
  • CIK0001656634
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address5959 Horton Street, Suite 300, Emeryville, CA 946081
  • Phone(510) 871-61001
  • Shares outstanding118,109,074 as of Aug 8, 202410
  • Public float$173.7M as of Jun 30, 20234
  • On EDGAR sinceMay 4, 20181
  • Filings426 in all: 4 (133), 8-K (65), SC 13G/A (35), 3 (28), SC 13G (20), 10-Q (18), CORRESP (16), EFFECT (11)1
    All 40 form types

    UPLOAD (11), S-8 (9), S-8 POS (9), DEFA14A (7), 10-K (6), DEF 14A (6), 4/A (5), 424B5 (5), S-3 (5), POS AM (4), 10-K/A (2), 424B3 (2), 424B4 (2), ARS (2), D (2), DRS (2), DRS/A (2), DRSLTR (2), S-1 (2), S-1/A (2), S-3/A (2), 144 (1), 15-12G (1), 25-NSE (1), 8-A12B (1), CERT (1), CT ORDER (1), S-1MEF (1), S-3ASR (1), SC 13D (1), SC 13D/A (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 5, 2024
    Quarterly report (10-Q) Aug 13, 2024
    Proxy statement (DEF 14A) Apr 29, 2024
    Latest 8-K (8-K) Apr 4, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
    SEC EDGAROther events
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70